Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer

Matthew D. Hellmann , Tavi Nathanson , Hira Rizvi , Matthew D. Hellmann , Tavi Nathanson , Hira Rizvi , Ben Creelan , Francisco Sánchez-Vega , Arun Ahuja , Ai Ni , Jacki B. Novik , Levi Mangarin , Mohsen Abu-Akeel , Cailian Liu , Jennifer L. Sauter , Natasha Rekhtman , Eliza Chang , Margaret K. Callahan , Jamie E. Chaft , Martin H. Voss , Megan Tenet , Xuemei Li , Kelly L. Covello , Andrea Renninger , Patrik Vitazka , William J. Geese , Hossein Borghaei , Charles M. Rudin , Scott Antonia , Charles Swanton , Jeff Hammerbacher , Taha Merghoub , Nicholas McGranahan , Alexandra Snyder , Jedd D. Wolchok
2018 Cancer Cell 1,147 citations

Abstract

Combination immune checkpoint blockade has demonstrated promising benefit in lung cancer, but predictors of response to combination therapy are unknown. Using whole-exome sequencing to examine non-small-cell lung cancer (NSCLC) treated with PD-1 plus CTLA-4 blockade, we found that high tumor mutation burden (TMB) predicted improved objective response, durable benefit, and progression-free survival. TMB was independent of PD-L1 expression and the strongest feature associated with efficacy in multivariable analysis. The low response rate in TMB low NSCLCs demonstrates that combination immunotherapy does not overcome the negative predictive impact of low TMB. This study demonstrates the association between TMB and benefit to combination immunotherapy in NSCLC. TMB should be incorporated in future trials examining PD-(L)1 with CTLA-4 blockade in NSCLC.

Keywords

BlockadeImmunotherapyLung cancerMedicineOncologyImmune checkpointCombination therapyPD-L1Targeted therapyCTLA-4Exome sequencingInternal medicineCancerCancer researchImmune systemT cellMutationImmunologyBiologyGeneReceptorGenetics

Affiliated Institutions

Related Publications

Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing

Hira Rizvi , Francisco Sánchez-Vega , Konnor La +29 more

Purpose Treatment of advanced non–small-cell lung cancer with immune checkpoint inhibitors (ICIs) is characterized by durable responses and improved survival in a subset of pati...

2018 Journal of Clinical Oncology 1371 citations

Publication Info

Year
2018
Type
article
Volume
33
Issue
5
Pages
843-852.e4
Citations
1147
Access
Closed

External Links

View on DOI.org

Social Impact

Altmetric
PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1147
OpenAlex

Cite This

Matthew D. Hellmann, Tavi Nathanson, Hira Rizvi et al. (2018). Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. Cancer Cell , 33 (5) , 843-852.e4. https://doi.org/10.1016/j.ccell.2018.03.018

Identifiers

DOI
10.1016/j.ccell.2018.03.018